TY  - JOUR
A1  - Sastre-Garriga, J
A1  - Pareto, D
A1  - Battaglini, M
A1  - Rocca, MA
A1  - Ciccarelli, O
A1  - Enzinger, C
A1  - Wuerfel, J
A1  - Sormani, MP
A1  - Barkhof, F
A1  - Yousry, TA
A1  - De Stefano, N
A1  - Tintoré, M
A1  - Filippi, M
A1  - Gasperini, C
A1  - Kappos, L
A1  - Río, J
A1  - Frederiksen, J
A1  - Palace, J
A1  - Vrenken, H
A1  - Montalban, X
A1  - Rovira, À
UR  - https://doi.org/10.1038/s41582-020-0314-x
VL  - 16
AV  - public
JF  - Nature Reviews Neurology
N2  - Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions ? the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.

Introduction
EP  - 182
KW  - Biomarkers
KW  -  Brain imaging
KW  -  Multiple sclerosis
ID  - discovery10092175
SP  - 171
PB  - Springer Science and Business Media LLC
N1  - This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article?s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article?s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
TI  - MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
Y1  - 2020/03//
ER  -